Trial Profile
Zoledronic acid for the prevention of osteoporosis in osteopenic patients undergoing allogeneic HCT
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2015
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 15 Dec 2012 New trial record
- 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
- 08 Dec 2012 Primary endpoint 'Lumbar-spine-bone-mineral-density' has been met.